AM-105

N/A

Report date: 2025/07/03 11:47:53

First In Class

Base Information

Drug NameAM-105

Drug Alias NameAM-105

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 stimulantsEpidermal growth factor receptor erbB1 modulators

TargetsTumor necrosis factor receptor superfamily member 9Epidermal growth factor receptor erbB1

Therapy Area/IndicationsColonic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbclon Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbclon Inc

Inactive CompaniesN/A

Active IndicationsColonic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A